Skip to main content
Clinical Trials/NCT03120026
NCT03120026
Completed
Not Applicable

A Whey Protein-based Nutritional Supplement Enriched in Vitamin D, Leucine and Calcium for Sarcopenia in Older Adults Undergoing Physical Rehabilitation the IRIS (Improving Rehabilitation In Sarcopenia) Study: a Randomized, Double-blind, Placebo-controlled Trial.

Azienda di Servizi alla Persona di Pavia2 sites in 1 country140 target enrollmentMay 10, 2017
ConditionsSarcopenia

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Sarcopenia
Sponsor
Azienda di Servizi alla Persona di Pavia
Enrollment
140
Locations
2
Primary Endpoint
Gait speed
Status
Completed
Last Updated
7 years ago

Overview

Brief Summary

This randomized, double-blind, placebo-controlled supplementation trial tested the hypothesis that nutritional supplementation with muscle-target nutritional supplementation concurrent with regular, controlled physical activity would increase the efficacy of physical rehabilitation in old adults suffering from sarcopenia

Detailed Description

This randomized, double-blind, placebo-controlled supplementation trial tested the hypothesis that nutritional supplementation with whey protein, essential amino acids - mainly leucine - vitamin D and calcium concurrent with regular, controlled physical activity would increase the efficacy of physical rehabilitation in old adults suffering from sarcopenia

Registry
clinicaltrials.gov
Start Date
May 10, 2017
End Date
December 19, 2018
Last Updated
7 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Azienda di Servizi alla Persona di Pavia
Responsible Party
Principal Investigator
Principal Investigator

Mariangela Rondanelli

Principal Investigator

Azienda di Servizi alla Persona di Pavia

Eligibility Criteria

Inclusion Criteria

  • age 65 years or older
  • admission for physical rehabilitation
  • sarcopenia, measured with bioelectrical impedance assessment (BIA) + handgrip strength and gait speed
  • Mini Mental State Examination ≥18
  • Informed consent

Exclusion Criteria

  • Any malignant disease during the last five years
  • Known kidney failure (previous glomerular filtration rate \<30 ml/min);
  • Known liver failure (Child B or C)
  • Psychiatric disease
  • Endocrine disorders associated with disorders of calcium metabolism (excluding osteoporosis)
  • Indications related to the study product:
  • More than 10 µg (400 IU) of daily Vitamin D intake from medical sources More than 500 mg of daily calcium intake from medical sources. Adherence to a high energy or high protein diet up or use of protein containing or amino acid containing nutritional supplements up to three months before starting the study.
  • Known allergy to milk, milk products or other components of the proposed interventions
  • Indication to or ongoing artificial nutrition support
  • Inclusion in other nutrition intervention trials

Outcomes

Primary Outcomes

Gait speed

Time Frame: 8 weeks

Change in gait speed (4-meter walking test)/month

Secondary Outcomes

  • Functional status - ADL(8 weeks)
  • Functional status - handgrip strength(8 weeks)
  • Costs(8 weeks)
  • Physical performance - Timed Up and Go test(8 weeks)
  • Functional status - Barthel(8 weeks)
  • Body weight(8 weeks)
  • Muscle mass(8 weeks)
  • Cognitive function - trail making test(8 weeks)
  • Physical performance - Tinetti(8 weeks)
  • Physical performance - chair-stand(8 weeks)
  • Quality of life(8 weeks)
  • Cognitive function - Mini Mental State Examination(8 weeks)
  • Adverse events(8 weeks)

Study Sites (2)

Loading locations...

Similar Trials